Enoch K. Kariuki
Director/Board Member bij ZENTALIS PHARMACEUTICALS, INC.
Vermogen: 601 733 $ op 31-03-2024
Profiel
Enoch K.
Kariuki is currently the Director at BIOCOM and the Independent Director at Zentalis Pharmaceuticals, Inc. He is also the Vice President at H.I.G.
BioHealth Partners LLC and the President at Endeavor BioMedicines, Inc. Dr. Kariuki previously served as the Co-Chief Executive Officer & Director at Lengo Therapeutics, Inc. He was also an Associate Director at UBS AG (New York) and an Independent Director at Imago BioSciences, Inc. from 2020 to 2023.
Additionally, he worked as a Principal at CVS Health Corp.
and a Senior Associate at Leerink Partners LLC.
From 2018 to 2020, he held the position of Senior Vice President-Corporate Development at Synthorx, Inc. He was the Chief Financial Officer at VelosBio, Inc. from 2020 to 2021.
Dr. Kariuki obtained a doctorate degree from Texas Southern University and an MBA from Tuck School of Business at Dartmouth.
Bekende belangen in openbare bedrijven
| Onderneming | Datum | Aantal aandelen | Totale waarde | Waarderingsdatum |
|---|---|---|---|---|
| 16-06-2023 | 38 181 ( 0.05% ) | 601 733 $ | 31-03-2024 |
Actieve functies van Enoch K. Kariuki
| Bedrijven | Functie | Begin |
|---|---|---|
| ZENTALIS PHARMACEUTICALS, INC. | Director/Board Member | 09-02-2021 |
H.I.G. BioHealth Partners LLC
 H.I.G. BioHealth Partners LLC Investment ManagersFinance H.I.G. BioHealth Partners LLC (H.I.G. BioHealth Partners) is a private equity and venture capital subsidiary of H.I.G. Ventures LLC founded in 1993. The firm is headquartered in Miami, Florida with additional offices around the globe. | Private Equity Investor | - |
BIOCOM
 BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Director/Board Member | 18-02-2021 |
Endeavor BioMedicines, Inc
 Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | President | 14-03-2024 |
Eerdere bekende functies van Enoch K. Kariuki
| Bedrijven | Functie | Einde |
|---|---|---|
| IMAGO BIOSCIENCES, INC. | Director/Board Member | 11-01-2023 |
VelosBio, Inc.
 VelosBio, Inc. Miscellaneous Commercial ServicesCommercial Services VelosBio, Inc. operates as an biopharmaceutical company. It developes antibody-drug conjugates to treat hematological cancers and solid tumors. The company was founded in 2017 and is headquartered in San Diego, CA. | Director of Finance/CFO | 01-01-2021 |
| SYNTHORX, INC. | Corporate Officer/Principal | 01-02-2020 |
Lengo Therapeutics, Inc.
 Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Chief Executive Officer | - |
UBS AG (New York)
 UBS AG (New York) Investment ManagersFinance UBS AG's (NYSE: UBS) New York City-based wealth management arm is known as UBS Private Banking (US). The firm provides a range of customized wealth management products and services for private clients. | Corporate Officer/Principal | - |
Opleiding van Enoch K. Kariuki
| Texas Southern University | Doctorate Degree |
| Tuck School of Business at Dartmouth | Masters Business Admin |
Ervaring
Beklede functies
Actief
Inactief
Beursgenoteerde bedrijven
Bedrijven in privébezit
Connecties
Eerstegraads connecties
Bedrijven verbonden in de eerste graad
Man
Vrouw
Besturend
Uitvoerend
Verwante bedrijven
| Beursgenoteerde bedrijven | 2 |
|---|---|
| CVS HEALTH CORPORATION | Retail Trade |
| ZENTALIS PHARMACEUTICALS, INC. | Health Technology |
| Bedrijven in privébezit | 9 |
|---|---|
UBS AG (New York)
UBS AG (New York) Investment ManagersFinance UBS AG's (NYSE: UBS) New York City-based wealth management arm is known as UBS Private Banking (US). The firm provides a range of customized wealth management products and services for private clients. | Finance |
Leerink Partners LLC
 Leerink Partners LLC Investment Banks/BrokersFinance Leerink Partners LLC is a full-service brokerage and investment banking firm headquartered in Boston, Massachusetts. The firm was founded by Jeffrey Leerink in 1995 and formerly known as SVB Securities LLC. They rebranded as Leerink Partners in 2023. The firm is a subsidiary of SVB Securities LLC. Leerink Partners provides institutional sales, equity research, institutional trading, and corporate finance and asset management services to the healthcare and technology industries. They offer superior execution capabilities in common stock, convertibles and derivatives with a singular focus on healthcare and a knowledge-led approach. | Finance |
BIOCOM
BIOCOM Miscellaneous Commercial ServicesCommercial Services BIOCOM provides scientific and technological services. The firm focuses that positively influence the growth of the life science industry, including capital formation, public policy, workforce development and scientific discovery and development. The company was founded in 1995 and is headquartered in San Diego, CA. | Commercial Services |
H.I.G. BioHealth Partners LLC
H.I.G. BioHealth Partners LLC Investment ManagersFinance H.I.G. BioHealth Partners LLC (H.I.G. BioHealth Partners) is a private equity and venture capital subsidiary of H.I.G. Ventures LLC founded in 1993. The firm is headquartered in Miami, Florida with additional offices around the globe. | Finance |
Synthorx, Inc.
 Synthorx, Inc. BiotechnologyHealth Technology Synthorx, Inc. focuses on prolonging and improving lives of cancer and autoimmune disorder patients. Its product pipeline is comprised of THOR-707, IL-2 Synthorin, IL-10 Synthorin, and IL-15 Synthorin. The company was founded by Floyd E. Romesberg and Court R. Turner in 2014 and is headquartered in La Jolla, CA. | Health Technology |
Imago BioSciences, Inc.
 Imago BioSciences, Inc. BiotechnologyHealth Technology Imago BioSciences, Inc. operates as a clinical-stage biopharmaceutical company that develops novel anti-cancer therapeutics. It translates science of genetics and epigenetics enzymes into novel medicines for treating myeloid diseases that pose challenges to patients, families, and physicians. The company also translates insights into transformative therapies that alter the history of disease allowing patients to live longer and disease-free lives. Imago BioSciences was founded by Hugh Young Rienhoff, Jr., Laura G. Eichorn and Jennifer Peppe on March 29, 2012 and is headquartered in Redwood City, CA. | Health Technology |
VelosBio, Inc.
VelosBio, Inc. Miscellaneous Commercial ServicesCommercial Services VelosBio, Inc. operates as an biopharmaceutical company. It developes antibody-drug conjugates to treat hematological cancers and solid tumors. The company was founded in 2017 and is headquartered in San Diego, CA. | Commercial Services |
Lengo Therapeutics, Inc.
Lengo Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Lengo Therapeutics, Inc. operates as a pharmaceutical company. The company is headquartered in Menlo Park, CA. | Health Technology |
Endeavor BioMedicines, Inc
Endeavor BioMedicines, Inc Miscellaneous Commercial ServicesCommercial Services Endeavor BioMedicines, Inc is a clinical stage company located in Solana Beach, CA, that develops novel therapies for fibrosis and oncology. The company's lead program, env-101, is a hedgehog signalling inhibitor currently in phase 2 studies treating IPF, a progressive interstitial lung disease that causes inflammation and scarring in the lung. The company's second program is a HER3-targeted ADC that will begin clinical development in 2024 for the treatment of multiple solid tumors. The company's mission is to develop transformative medicines by targeting the underlying genetic and cellular causes of disease with best in class agents. Endeavor is partnered with XCures and is currently looking at the LOF mutation. Regardless of eligibility for the Endeavor trial, XCures will still send a list of other treatment options that could work for the cancer mutation. The company was founded by Miguel A. de los Ríos and John Hood, with John Hood serving as the CEO since incorporation. | Commercial Services |
